Just Released: Umbrella Labs Facts about GW-501516

February 07, 2023

Tucson, Arizona - February 07, 2023 - PRESSADVANTAGE -

GW501516 (Cardarine) is a compound that acts as a PPAR? modulator. It is often grouped with sarms when it is discussed and sold on research sites but it would fall under a different category scientifically. It is often researched together with other sarms and various research products, thus the grouping and association amongst researchers. Pre-clinical studies determined that GW 501516 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue as well as demonstrating capabilities to reverse metabolic abnormalities in obese subjects with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions as the combination has been shown to significantly increase exercise endurance in animal studies.

How it works: GW501516 is a selective agonist (activator) of the PPAR? receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPAR? with > 1000 fold selectivity over PPAR? and PPAR?.

In studies conducted on rats, the binding of GW501516 to PPAR? recruits the coactivator PGC-1a. The PPAR?/coactivator complex then in turn regulates the expression of proteins involved in energy expenditure. Furthermore, in rats treated with GW501516, there was increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity. In obese rhesus monkeys, GW501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPAR? agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.

Main research uses: The following are anecdotal analysis that have been determined over time by researchers on rats to find other benefits with GW-501516.

The main conclusion drawn by researchers from pre-clinical studies is the endurance benefit observed in mice. The compound itself was banned by the WADA and the NCAA due to the apparent advantages it could provide, which could potentially validate the findings or it could be precautionary on their part. Mice have shown to have quite drastic endurance increases.

The next main finding is that of fat loss. Pre-clinical studies made by researchers have found a strong

capability in rats for fat loss and metabolism increases over short periods of time. The pre-clinical studies are

often conducted between 4-12 weeks on rats with differing doses for testing. These are all accessible online

on various websites.

One other substantial pre-clinical finding on rats is the ability to lower LDL (bad cholesterol), raise good

cholesterol (HDL) as well as lowering blood pressure. These are all pre-clinical and anecdotal findings that

are quite prevalent throughout the internet.

In conclusion, the pre-clinical data on GW 501516 is extremely promising and the compound has grown in

interest for research over the years, with intrigue and interest in it?s structure and capability to be growing by

the day.

Umbrella Labs takes pride in the efficacy and quality of their research products, allowing a researcher to have

the opportunity to obtain true and accurate findings on their research, unlike many other research companies

who do not take the mindful approach of putting true and accurate research first. Umbrella Labs ensures that

proper research results can be conducted and the researcher is always put first.

###

For more information about Umbrella Labs , contact the company here:Umbrella Labs Kristin

McFadden415-988-7551kmcfadden@umbrella-labs.us3280 E Hemisphere Loop Tucson, AZ 85706

Umbrella Labs

Umbrella Labs takes pride in not only providing products and chemicals of the highest quality, but the best customer

service in the industry.

Website: https://umbrellalabs.is

Email: kmcfadden@umbrella-labs.us

Phone: 415-988-7551

Powered by PressAdvantage.com